These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20175855)

  • 1. Cutaneous reactions following subcutaneous beta-interferon-1b injection.
    Ohata U; Hara H; Yoshitake M; Terui T
    J Dermatol; 2010 Feb; 37(2):179-81. PubMed ID: 20175855
    [No Abstract]   [Full Text] [Related]  

  • 2. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient.
    Ozden MG; Erel A; Erdem O; Oztas MO
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):112-3. PubMed ID: 15649205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Livedo reticularis following subcutaneous injection of interferon beta-1b].
    Rodríguez-Vico JS; Mendoza A; Duarte J
    Rev Neurol; 2010 Jul; 51(1):62. PubMed ID: 20568071
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrent injection site reactions from interferon beta 1-b.
    Samuel L; Lowenstein EJ
    J Drugs Dermatol; 2006 Apr; 5(4):366-7. PubMed ID: 16673806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study.
    Lanzillo R; Moccia M; Carotenuto A; Vacchiano V; Satelliti B; Panetta V; Brescia Morra V
    Mult Scler; 2015 Aug; 21(9):1215-6. PubMed ID: 25662354
    [No Abstract]   [Full Text] [Related]  

  • 8. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
    Serarslan G; Okuyucu E; Melek I; Hakverdi S; Duman T
    Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous ulcerations following subcutaneous interferon beta injection to a patient with multiple sclerosis.
    Inafuku H; Kasem Khan MA; Nagata T; Nonaka S
    J Dermatol; 2004 Aug; 31(8):671-7. PubMed ID: 15492442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
    Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
    Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
    Oger J; Francis G; Chang P;
    J Neurol Sci; 2005 Oct; 237(1-2):45-52. PubMed ID: 16026803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta-1b (Extavia) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):86-7. PubMed ID: 21045760
    [No Abstract]   [Full Text] [Related]  

  • 14. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retinopathy secondary to treatment with Interferon beta-1a in a patient with multiple sclerosis].
    Mallada-Frechín J; Abellán-Miralles I; Alfaro-Beltra ML; Medrano V; Muñoz-Gil MB; Fernández-Izquierdo S; Piqueras-Rodríguez L
    Rev Neurol; 2005 Apr 16-30; 40(8):482-4. PubMed ID: 15861330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous necrosis associated with recombinant interferon injection.
    Weinberg JM
    J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):807-8. PubMed ID: 9810903
    [No Abstract]   [Full Text] [Related]  

  • 17. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon β.
    Melanson M; Grossberndt A; Klowak M; Leong C; Frost EE; Prout M; Le Dorze JA; Gramlich C; Doupe M; Wong L; Esfahani F; Gomori A; Namaka M
    Int J Neurosci; 2010 Oct; 120(10):631-40. PubMed ID: 20942577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis.
    Szilasiová J; Gdovinová Z; Jautová J; Baloghová J; Ficová M; Bohus P
    Clin Neuropharmacol; 2009; 32(5):301-3. PubMed ID: 19820436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
    Ball NJ; Cowan BJ; Hashimoto SA
    J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.